FDA — Food and Drug Administration logo
FDA — Food and Drug Administration

Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases

Funds natural history studies that track how a rare disease unfolds over time, to close data gaps blocking new treatments for it.

Before anyone can design a trial for a rare disease, someone has to know how that disease actually behaves over time — how fast it progresses, what changes first, what a meaningful improvement even looks like. For many rare diseases nobody has collected that information yet.

This notice funds building it: natural history studies that produce high-quality, interpretable data on a specific rare dis

Natural history studies producing high-quality, interpretable data on a rare disease or a group of related rare diseases with shared underlying biology, aimed at closing knowledge gaps and feeding into medical product development. Clinical trials are optional under this activity code.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.One-off
Next deadlineiThe next date applications are due. Rolling means you can apply any time.8 Feb 2028
Decision timeiTypical time from the deadline to the funder's decision.
Project durationiHow long the funded work is expected to run.
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.
Funding pooliThe total budget available across all awards in this round.

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 25 Aug 2026Funder reference: RFA-FD-25-017Source: www.grants.gov